[Prinzmetal angina].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology*; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000150:complications; D001285:Atropine / Q000627:therapeutic use; D001794:Blood Pressure; D006328:Cardiac Catheterization; D002395:Catecholamines / Q000097:blood; D001026:Coronary Artery Bypass; D003331:Coronary Vessels; D004087:Dihydroergotamine / Q000009:adverse effects; D004285:Dogs; D006339:Heart Rate; D006801:Humans; D009129:Muscle Tonus; D009203:Myocardial Infarction / Q000209:etiology; D005996:Nitroglycerin / Q000627:therapeutic use; D009756:Nylidrin / Q000627:therapeutic use; D005082:Physical Exertion; D012146:Rest
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D004087:Dihydroergotamine; D009756:Nylidrin; D001285:Atropine; D005996:Nitroglycerin
Prinzmetal-Angina